Equity Profile

FMS

Fresenius Medical Care AG

Health CareHealth Care Services$13.1B

Aug4Tue

Pre-Earnings Brief

UpcomingQ2-2023After Close9:00 AM EDT

Company Snapshot

Fresenius Medical Care AG is a leading provider of products and services for individuals with renal diseases. Operating in the health care sector, the company plays a crucial role in dialysis services and related health care services, catering to a growing patient population worldwide.

Key Metrics to Watch

EPS

Earnings per share is a key indicator of profitability and will show how well the company is managing its costs and revenues.

$0.50

Revenue

Total revenue reflects the company’s ability to grow its business and capture market share in the health care services industry.

$4.6B

Wall Street expectations, options signals, track record, and call prep available with Pro.

FMS Q2-2023 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

25%

Avg EPS Surprise

-6.74%

Avg Stock Reaction

-1.23%

Last Quarter Recap

In Q1 2023, Fresenius Medical Care reported an EPS of $0.17, which was slightly below the expected $0.18. The stock reacted with a minor decline of 0.09% the following day.

Management Promises & Guidance

Expectations

Wall Street Expectations

Analysts are cautiously optimistic about Fresenius Medical Care's upcoming earnings, with expectations for a modest recovery in EPS and revenue growth. The consensus estimates suggest a slight improvement compared to the previous quarter.

Bull Case

If Fresenius exceeds the EPS estimate of $0.50, it could indicate a strong rebound in profitability, potentially leading to increased investor confidence and a positive stock reaction.

Bear Case

Conversely, if the company misses its EPS target again, it may raise concerns about ongoing operational challenges, leading to a negative market reaction.

Key Metrics to Watch

EPS

$0.50

Earnings per share is a key indicator of profitability and will show how well the company is managing its costs and revenues.

Revenue

$4.6B

Total revenue reflects the company’s ability to grow its business and capture market share in the health care services industry.

Expectations

Two Questions That Matter

The print will turn on these two things.

Will the EPS exceed the consensus estimate of $0.50?

A beat on EPS could signal a turnaround in profitability, which is critical for restoring investor confidence.

What are the revenue figures compared to the consensus of $4.6B?

Revenue growth is essential for the company’s long-term health and will indicate its ability to capture market share.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be underestimating the potential for a rebound in demand for dialysis services, which could lead to better-than-expected results this quarter.

Supporting Evidence

The options market is pricing a 24.8% move, indicating expectations for volatility that may not align with the actual performance.

Fresenius has historically shown resilience in recovering from earnings misses, which could suggest a potential upside this quarter.

Key Risk

If the revenue comes in above $4.7B, it could significantly shift the narrative towards a recovery.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The market is weighing the company's ability to recover from recent earnings misses against the backdrop of growing demand for health care services.

Bull Confirmed If

An EPS of $0.53 or higher, coupled with revenue exceeding $4.7B, would confirm the bull case.

Bear Confirmed If

An EPS below $0.47 and revenue under $4.5B would support the bear case.

Pre-Earnings Positioning

Options Market

Implied Move

±24.8%

Historical Avg

±2.7%

Pricing rich

The options market is pricing in a significant potential move, suggesting that investors expect considerable volatility around the earnings announcement.

Options are pricing ±24.8% while FMS has averaged ±2.7% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.5%

30d HV

44.1%

Calls (500)P/C Ratio: 1.60Puts (800)

Edge

Institutional Ownership

Smart-money positioning from the most recent 13F filings.

Top holders trimming

Institutional

8.64%

of float

Insider

0.00%

of float

Holders

255

institutions

Top Holders· as of Dec 2025

Pzena Investment Management LLC
14,752,836 sh · $335.9M
2.64%
-0.4%

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Fresenius beats expectations, history suggests the stock could see a modest positive reaction, potentially around a 2.69% increase.

In-Line / Cautious

If results are in line with expectations, the stock may experience muted movement as investors await further guidance.

Miss

A miss could lead to a decline, with historical patterns indicating an average drop of around 1.23%.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Updates on patient enrollment and demand for dialysis services.
2Any commentary on cost management and operational efficiencies.
3Insights into market share changes in the health care services sector.
4Guidance on future revenue growth and profitability targets.
5Discussion of any new product launches or service expansions.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime

More Earnings This Week

5 Reports

Aug3

ONBMO

ON Semiconductor Corporation

PreviewView

Aug3

LBMO

Company Snapshot

Key Metrics to Watch

EPS

Earnings per share is a key indicator of profitability and will show how well the company is managing its costs and revenues.

$0.50

Revenue

Total revenue reflects the company’s ability to grow its business and capture market share in the health care services industry.

$4.6B

Wall Street expectations, options signals, track record, and call prep available with Pro.

FMS Q2-2023 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

25%

Avg EPS Surprise

-6.74%

Avg Stock Reaction

-1.23%

Last Quarter Recap

In Q1 2023, Fresenius Medical Care reported an EPS of $0.17, which was slightly below the expected $0.18. The stock reacted with a minor decline of 0.09% the following day.

Management Promises & Guidance

Expectations

Wall Street Expectations

Bull Case

If Fresenius exceeds the EPS estimate of $0.50, it could indicate a strong rebound in profitability, potentially leading to increased investor confidence and a positive stock reaction.

Bear Case

Conversely, if the company misses its EPS target again, it may raise concerns about ongoing operational challenges, leading to a negative market reaction.

Key Metrics to Watch

EPS

$0.50

Earnings per share is a key indicator of profitability and will show how well the company is managing its costs and revenues.

Revenue

$4.6B

Total revenue reflects the company’s ability to grow its business and capture market share in the health care services industry.

Expectations

Two Questions That Matter

The print will turn on these two things.

Will the EPS exceed the consensus estimate of $0.50?

A beat on EPS could signal a turnaround in profitability, which is critical for restoring investor confidence.

What are the revenue figures compared to the consensus of $4.6B?

Revenue growth is essential for the company’s long-term health and will indicate its ability to capture market share.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be underestimating the potential for a rebound in demand for dialysis services, which could lead to better-than-expected results this quarter.

Supporting Evidence

The options market is pricing a 24.8% move, indicating expectations for volatility that may not align with the actual performance.

Fresenius has historically shown resilience in recovering from earnings misses, which could suggest a potential upside this quarter.

Key Risk

If the revenue comes in above $4.7B, it could significantly shift the narrative towards a recovery.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The market is weighing the company's ability to recover from recent earnings misses against the backdrop of growing demand for health care services.

Bull Confirmed If

An EPS of $0.53 or higher, coupled with revenue exceeding $4.7B, would confirm the bull case.

Bear Confirmed If

An EPS below $0.47 and revenue under $4.5B would support the bear case.

Pre-Earnings Positioning

Options Market

Implied Move

±24.8%

Historical Avg

±2.7%

Pricing rich

The options market is pricing in a significant potential move, suggesting that investors expect considerable volatility around the earnings announcement.

Options are pricing ±24.8% while FMS has averaged ±2.7% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.5%

30d HV

44.1%

Calls (500)P/C Ratio: 1.60Puts (800)

Edge

Institutional Ownership

Smart-money positioning from the most recent 13F filings.

Top holders trimming

Institutional

8.64%

of float

Insider

0.00%

of float

Holders

255

institutions

Top Holders· as of Dec 2025

Pzena Investment Management LLC
14,752,836 sh · $335.9M
2.64%
-0.4%

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Fresenius beats expectations, history suggests the stock could see a modest positive reaction, potentially around a 2.69% increase.

In-Line / Cautious

If results are in line with expectations, the stock may experience muted movement as investors await further guidance.

Miss

A miss could lead to a decline, with historical patterns indicating an average drop of around 1.23%.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Updates on patient enrollment and demand for dialysis services.
2Any commentary on cost management and operational efficiencies.
3Insights into market share changes in the health care services sector.
4Guidance on future revenue growth and profitability targets.
5Discussion of any new product launches or service expansions.